ARA 290 (acetate)
(Synonyms: Cibinetide, PHBSP, Pyroglutamate HBSP, Pyroglutamate Helix B Surface Peptide) 目录号 : GC49473
A derivative of EPO
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
ARA 290 is a derivative of erythropoietin (EPO).1 In vivo, ARA 290 (0.8 and 8 nmol/kg, i.p.) reduces plasma creatine, urea, and aspartate aminotransferase (AST) levels, markers of renal dysfunction, in a rodent model of renal ischemia-reperfusion injury. It decreases wound area in a rat model of punch biopsy-induced dermal injury and a rat model of decubitus ulcer.2 ARA 290 (30 µg/kg, i.p.) reduces the latency to find the platform in the Morris water maze in a rat model of cortical impact-induced traumatic brain injury (TBI).3 It also reduces tactile allodynia in a rat model of neuropathic pain induced by spinal nerve injury (SNI).4
1.Brines, M., Patel, N.S.A., Villa, P., et al.Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProc. Natl. Acad. Sci. USA105(31)10925-10930(2008) 2.Erbayraktar, Z., Erbayraktar, S., Yilmaz, O., et al.Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healingMol. Med.15(7-8)235-241(2009) 3.Robertson, C.S., Garcia, R., Gaddam, S.S.K., et al.Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptideJ. Neurotrauma30(9)765-774(2013) 4.Swartjes, M., Niesters, M., and Dahan, A.Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic painMethods Mol. Biol.982187-195(2013)
| Cas No. | N/A | SDF | Download SDF |
| 别名 | Cibinetide, PHBSP, Pyroglutamate HBSP, Pyroglutamate Helix B Surface Peptide | ||
| Canonical SMILES | OC([C@H](CO)NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC([C@H](CCC(O)=O)NC([C@@H]1CCC(N1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O | ||
| 分子式 | C51H84N16O21 • XC2H4O2 | 分子量 | 1257.3 |
| 溶解度 | DMF: insol,DMSO: 5 mg/ml,Ethanol: insol,PBS (pH 7.2): insol | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7954 mL | 3.9768 mL | 7.9536 mL |
| 5 mM | 0.1591 mL | 0.7954 mL | 1.5907 mL |
| 10 mM | 0.0795 mL | 0.3977 mL | 0.7954 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。